搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
The American Journal of Managed Care
1 小时
How to Choose Between Fixed-Duration vs Continuous BTKi Therapy for CLL
Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health, discussed the ...
healthandpharma
4 小时
Fixed-Duration Acalabrutinib Plus Venetoclax Achieves Superior 77% PFS in Untreated CLL
The AMPLIFY Phase III trial demonstrates that acalabrutinib plus venetoclax significantly improves progression-free survival ...
Targeted Oncology
11 分钟
Pirtobrutinib Boosts PFS and Sustains BTK Inhibition in Patients With CLL/SLL
Pirtobrutinib, a third-generation BTK inhibitor, showed superior progression-free survival and lower treatment ...
Targeted Oncology
1 小时
Sonrotoclax and Zanubrutinib Shows Strong Efficacy in Untreated CLL/SLL
Initial therapy with sonrotoclax and zanubrutinib showed strong efficacy and acceptable safety in untreated CLL/SLL.
The American Journal of Managed Care
2 小时
6-Year Data Support Fixed-Duration Ven-Obi for Untreated CLL
Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic ...
1 天
on MSN
Clinical trials reveal combining inhibitors shows promise in chronic lymphocytic leukemia
A novel, fixed-duration drug combination—consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 ...
MyChesCo on MSN
2 小时
NCCN Awards New Grants to Improve Care for CLL/SLL Patients
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announced the distribution of quality ...
FiercePharma
2 天
ASH: AstraZeneca proposes fixed-duration Calquence combos in chronic lymphocytic leukemia
Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...
MedPage Today
23 小时
Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting
SAN DIEGO -- A fixed-duration oral combination significantly reduced the risk of disease progression or death compared with ...
News Medical
12 小时
New triplet therapies show promise for relapsed and newly diagnosed leukemias
Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant ...
FiercePharma
19 小时
ASH: Eli Lilly touts novel BTK trial win for Jaypirca as execs defend survival data blemish
With a positive phase 3 trial in chronic lymphocytic leukemia (CLL), Eli Lilly hopes to convert Jaypirca’s unique accelerated ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈